Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine

International Journal of Biochemistry and Cell Biology

Volumn 60, Issue , 2015, Pages 73-81

  Honeywell, Richard J ^a   Ruiz Van Haperen, Veronique W T ^a,b   Veerman, Gijsbert ^a,c   Smid, Kees ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Health Research and Development Council   (Netherlands)

^c SYNEOS HEALTH   (United States)

Author keywords

2 2 Difluoro 2 deoxycytidine; 2 2 Difluoro 2 deoxyuridine; Cytidine analogues; Thymidylate synthase

Indexed keywords

2',2' DIFLUORO 2' DEOXYURIDINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DEOXYURIDINE; GEMCITABINE; RALTITREXED; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE; 2',2'-DIFLUORO-2'-DEOXYURIDINE; FLOXURIDINE;

ARTICLE; BINDING SITE; CELL DAMAGE; CHEMOSENSITIVITY; COMPLEX FORMATION; CONTROLLED STUDY; DEAMINATION; DNA DAMAGE; DNA DENATURATION; DNA STRAND BREAKAGE; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; LEUKEMIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OVARY CARCINOMA; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; DEOXYCYTIDINE; DNA DAMAGE; ENZYME ACTIVATION; FLOXURIDINE; HUMANS; THYMIDYLATE SYNTHASE;

EID: 84920993361     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2014.12.010     Document Type: Article

References (33)

1. J.L. Abbruzzese, R. Grunewald, E.A. Weeks, D. Gravel, T. Adams, and B. Nowak A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 1991 491 498
2. A. Azuma, P. Huang, A. Matsuda, and W. Plunkett 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest Mol Pharmacol 59 2001 725 731
3. A.M. Bergman, H.M. Pinedo, and G.J. Peters Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) Drug Resist Updat 5 2002 19 33
4. A.M. Bergman, P.P. Eijk, V.W. Ruiz van Haperen, K. Smid, G. Veerman, and I. Hubeek In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant Cancer Res 65 2005 9510 9516
5. J. Carmichael The role of gemcitabine in the treatment of other tumours Br J Cancer 78 Suppl. 3 1998 21 25
6. C.W. Carreras, and D.V. Santi The catalytic mechanism and structure of thymidylate synthase Annu Rev Biochem 64 1995 721 762
7. E. Chu, and C.J. Allegra The role of thymidylate synthase as an RNA binding protein Bioessays 18 1996 191 198
8. S.M. de Lange, K. Van der Born, J.R. Kroep, H.A. Jensen, P. Pfeiffer, and A. Cleverly No evidence of gemcitabine accumulation during weekly administration Eur J Clin Pharmacol 61 2005 843 849
9. K. Erixon, and G. Ahnstrom Single-strand breaks in DNA during repair of UV-induced damage in normal human and xeroderma pigmentosum cells as determined by alkaline DNA unwinding and hydroxylapatite chromatography: effects of hydroxyurea, 5-fluorodeoxyuridine and 1-beta-D-arabinofuranosylcytosine on the kinetics of repair Mutat Res 59 1979 257 271
10. V. Heinemann Gemcitabine: progress in the treatment of pancreatic cancer Oncology 60 2001 8 18
11. V. Heinemann, L.W. Hertel, G.B. Grindey, and W. Plunkett Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine Cancer Res 48 1988 4024 4031
12. V. Heinemann, Y.Z. Xu, S. Chubb, A. Sen, L.W. Hertel, and G.B. Grindey Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine Mol Pharmacol 38 1990 567 572
13. V. Heinemann, Y.Z. Xu, S. Chubb, A. Sen, L.W. Hertel, and G.B. Grindey Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation Cancer Res 52 1992 533 539
14. L.W. Hertel, G.B. Boder, J.S. Kroin, S.M. Rinzel, G.A. Poore, and G.C. Todd Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) Cancer Res 50 1990 4417 4422
15. R.J. Honeywell, E. Giovannetti, and G.J. Peters Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS Nucleosides Nucleotides Nucleic Acids 30 2011 1203 1213
16. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, and W. Plunkett Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res 51 1991 6110 6117
17. Y.P. Keepers, P.E. Pizao, G.J. Peters, J. van Ark-Otte, B. Winograd, and H.M. Pinedo Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing Eur J Cancer 27 1991 897 900
18. C. Manegold Gemcitabine (Gemzar) in non-small cell lung cancer Expert Rev Anticancer Ther 4 2004 345 360
19. B. Pauwels, A.E. Korst, H.A. Lambrechts, G.G. Pattyn, C.M. De Pooter, and F. Lardon The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro Cancer Chemother Pharmacol 58 2006 219 228
20. G.J. Peters, E. Laurensse, A. Leyva, J. Lankelma, and H.M. Pinedo Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes Cancer Res 46 1986 20 28
21. G.J. Peters, C.L. Van der Wilt, C.J. Van Groeningen, K. Smid, S. Meijer, and H.M. Pinedo Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil J Clin Oncol 12 1994 2035 2042
22. G.J. Peters, M. Clavel, P. Noordhuis, G.J. Geyssen, A.C. Laan, and J. Guastalla Clinical phase I and pharmacology study of gemcitabine (2′,2′-difluorodeoxycytidine) administered in a two-weekly schedule J Chemother 19 2007 212 221
23. W. Plunkett, P. Huang, C.E. Searcy, V. Gandhi, and Gemcitabine: preclinical pharmacology and mechanisms of action Semin Oncol 23 1996 3 15
24. V.W. Ruiz van Haperen, G. Veerman, J.B. Vermorken, and G.J. Peters 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Biochem Pharmacol 46 1993 762 766
25. V.W. Ruiz van Haperen, G. Veerman, S. Eriksson, E. Boven, A.P. Stegmann, and M. Hermsen Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780 Cancer Res 54 1994 4138 4143
26. K. Smid, A.M. Bergman, P.P. Eijk, G. Veerman, V.W. Ruiz van Haperen, and P. van den Ijssel Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits Nucleosides Nucleotides Nucleic Acids 25 2006 1001 1007
27. T. Thigpen The role of gemcitabine in first-line treatment of advanced ovarian carcinoma Semin Oncol 33 2006 S26 S32
28. C.L. Van der Wilt, C.M. Kuiper, and G.J. Peters Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines Oncol Res 11 1999 383 391
29. C.L. Van der Wilt, K. Smid, and G.J. Peters Effects of antifolates on the binding of 5-fluoro-2′-deoxyuridine monophosphate to thymidylate synthase Biochem Pharmacol 64 2002 669 675
30. C.J. Van Moorsel, J.R. Kroep, H.M. Pinedo, G. Veerman, D.A. Voorn, and P.E. Postmus Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors Ann Oncol 10 1999 441 448
31. N.L. Vasilenko, and G.A. Nevinsky Pathways of accumulation and repair of deoxyuridine residues in DNA of higher and lower organisms Biochemistry (Mosc) 68 2003 135 151
32. A. Wouters, B. Pauwels, N. Burrows, M. Baay, V. Deschoolmeester, and T.N. Vu The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein BMC Cancer 14 2014 594
33. Y.Z. Xu, and W. Plunkett Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells J Biol Chem 268 1993 22363 22368